171 related articles for article (PubMed ID: 30429449)
21. Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC.
Tan AC; Seet AOL; Lai GGY; Lim TH; Lim AST; Tan GS; Takano A; Tai DWM; Tan TJY; Lam JYC; Ng MCH; Tan WL; Ang MK; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim WT; Tan EH; Lim TKH; Tan DSW
J Thorac Oncol; 2020 Dec; 15(12):1928-1934. PubMed ID: 32866654
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
Takeuchi S; Murayama T; Yoshimura K; Kawakami T; Takahara S; Imai Y; Kuribayashi Y; Nagase K; Goto K; Nishio M; Hasegawa Y; Satouchi M; Kiura K; Seto T; Yano S
J Med Invest; 2017; 64(3.4):317-320. PubMed ID: 28955006
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
Horiike A; Takeuchi K; Uenami T; Kawano Y; Tanimoto A; Kaburaki K; Tambo Y; Kudo K; Yanagitani N; Ohyanagi F; Motoi N; Ishikawa Y; Horai T; Nishio M
Lung Cancer; 2016 Mar; 93():43-6. PubMed ID: 26898613
[TBL] [Abstract][Full Text] [Related]
24. RET/PTC rearrangement occurring in primary peritoneal carcinoma.
Flavin R; Jackl G; Finn S; Smyth P; Ring M; O'Regan E; Cahill S; Unger K; Denning K; Jinghuan Li ; Aherne S; Tallini G; Gaffney E; O'Leary JJ; Zitzelsberger H; Sheils O
Int J Surg Pathol; 2009 Jun; 17(3):187-97. PubMed ID: 19147513
[TBL] [Abstract][Full Text] [Related]
25. Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report.
Riudavets M; Caramella C; Pradere P; Naltet C; Le Pechoux C; Adam J; Mabille L; Rouleau E; Besse B; Planchard D
Clin Lung Cancer; 2021 Mar; 22(2):e215-e219. PubMed ID: 33187915
[No Abstract] [Full Text] [Related]
26. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
Wijesinghe P; Bepler G; Bollig-Fischer A
J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
[TBL] [Abstract][Full Text] [Related]
27. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
Platt A; Morten J; Ji Q; Elvin P; Womack C; Su X; Donald E; Gray N; Read J; Bigley G; Blockley L; Cresswell C; Dale A; Davies A; Zhang T; Fan S; Fu H; Gladwin A; Harrod G; Stevens J; Williams V; Ye Q; Zheng L; de Boer R; Herbst RS; Lee JS; Vasselli J
BMC Cancer; 2015 Mar; 15():171. PubMed ID: 25881079
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
[TBL] [Abstract][Full Text] [Related]
29. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
[TBL] [Abstract][Full Text] [Related]
30. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
[TBL] [Abstract][Full Text] [Related]
31. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
32. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
33. RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer.
Sasaki H; Shimizu S; Tani Y; Maekawa M; Okuda K; Yokota K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Cancer Med; 2012 Aug; 1(1):68-75. PubMed ID: 23342255
[TBL] [Abstract][Full Text] [Related]
34. Diagnostics, therapeutics and RET inhibitor resistance for RET fusion-positive non-small cell lung cancers and future perspectives.
Lu C; Zhou Q
Cancer Treat Rev; 2021 May; 96():102153. PubMed ID: 33773204
[TBL] [Abstract][Full Text] [Related]
35. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
[TBL] [Abstract][Full Text] [Related]
36. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
37. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Morano F; Fucà G; Nikolinakos P; Drilon A; Hechtman JF; Christiansen J; Gowen K; Frampton GM; Gasparini P; Rossini D; Gigliotti C; Kim ST; Prisciandaro M; Hodgson J; Zaniboni A; Chiu VK; Milione M; Patel R; Miller V; Bardelli A; Novara L; Wang L; Pupa SM; Sozzi G; Ross J; Di Bartolomeo M; Bertotti A; Ali S; Trusolino L; Falcone A; de Braud F; Cremolini C
Ann Oncol; 2018 Jun; 29(6):1394-1401. PubMed ID: 29538669
[TBL] [Abstract][Full Text] [Related]
38. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
[TBL] [Abstract][Full Text] [Related]
39. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
40. Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1.
Musholt TJ; Brehm C; Hanack J; von Wasielewski R; Musholt PB
J Surg Res; 2006 Mar; 131(1):15-25. PubMed ID: 16256137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
